VolitionRx H1 2026 revenue up 112%, expanding clinical and commercial ops
VolitionRx reported a 112% year-over-year revenue increase in the first half of 2026, reaching $1.4 million as it broadened both clinical and commercial operations. The result signals momentum for its diagnostics platform, potentially enabling partnerships or non-dilutive funding if growth sustains. Investors will focus on continued top-line progression and any profitability milestones in H2 2026.
View signal analysis